Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Gains from Sales and Divestitures (2024 - 2025)

Historic Gains from Sales and Divestitures for Immucell (ICCC) over the last 6 years, with Q2 2025 value amounting to $92000.0.

  • Immucell's Gains from Sales and Divestitures changed N/A to $92000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $92000.0, marking a year-over-year change of. This contributed to the annual value of $54000.0 for FY2024, which is N/A changed from last year.
  • Latest data reveals that Immucell reported Gains from Sales and Divestitures of $92000.0 as of Q2 2025.
  • In the past 5 years, Immucell's Gains from Sales and Divestitures ranged from a high of $92000.0 in Q2 2025 and a low of $47000.0 during Q1 2025